Physician profile
Kurt K Devito
NPI 1780630863
$53,625.90
in general payments reported to CMS, 2019-2025
14 companies · $10K in 2025
The $10K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $730 · 2021: $1,625 · 2022: $3,063 · 2023: $11K · 2024: $26K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $45K · Food and Beverage: $1,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $45,256.69 |
| Food and Beverage | $1,866.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $47,987.21 | 2019-2025 | Contact Lens, Spectacle Lenses |
| Coopervision INC. | $3,069.93 | 2019-2025 | Myday Contact Lens, Biofinity Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $838.35 | 2022-2024 | Infuse, Miebo, Biotrue One Day |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $816.47 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $309.74 | 2019-2024 | Cequa |
| Abbvie INC. | $254.83 | 2022-2024 | Durysta |
| Novartis Pharmaceuticals Corporation | $109.54 | 2020-2023 | |
| Oyster Point Pharma, INC. | $84.85 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $49.95 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $32.05 | 2020 | |
| Maculogix, INC. | $26.51 | 2020 | |
| Shire North American Group INC | $18.96 | 2019 | |
| Alcon Vision LLC | $14.58 | 2019 | |
| Oasis Medical, INC. | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Devito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.